Oarsman Capital Inc. Makes New $5.03 Million Investment in AstraZeneca PLC $AZNCF

Oarsman Capital Inc. bought a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 28,644 shares of the company’s stock, valued at approximately $5,027,000. AstraZeneca accounts for about 0.7% of Oarsman Capital Inc.’s investment portfolio, making the stock its 23rd biggest position.

Other large investors have also recently made changes to their positions in the company. Hughes Financial Services LLC purchased a new stake in shares of AstraZeneca during the fourth quarter valued at $34,000. Mascoma Wealth Management LLC purchased a new stake in shares of AstraZeneca during the fourth quarter valued at $46,000. Resources Management Corp CT ADV purchased a new stake in shares of AstraZeneca during the fourth quarter valued at $61,000. Triumph Capital Management purchased a new stake in shares of AstraZeneca during the fourth quarter valued at $75,000. Finally, Elyxium Wealth LLC purchased a new stake in shares of AstraZeneca during the fourth quarter valued at $102,000. 40.87% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

Shares of AZNCF opened at $187.10 on Tuesday. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00. The firm has a fifty day moving average price of $187.10 and a 200-day moving average price of $185.99.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.